Qiagen N.V. (FRA:QIA)

Germany flag Germany · Delayed Price · Currency is EUR
40.49
-0.05 (-0.12%)
Last updated: Jun 23, 2025
1.71%
Market Cap 8.89B
Revenue (ttm) 1.85B
Net Income (ttm) 86.67M
Shares Out n/a
EPS (ttm) 0.39
PE Ratio 102.61
Forward PE 20.06
Dividend 1.21 (2.98%)
Ex-Dividend Date Jan 29, 2025
Volume 376
Average Volume 520
Open 40.51
Previous Close 40.54
Day's Range 40.39 - 40.70
52-Week Range 32.50 - 47.53
Beta n/a
RSI 63.27
Earnings Date Jul 28, 2025

About Qiagen

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and... [Read more]

Industry Laboratory Analytical Instruments
Founded 1984
Employees 5,396
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol QIA
Full Company Profile

Financial Performance

In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.

Financial numbers in USD Financial Statements

News

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (A...

21 hours ago - Wallstreet:Online

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman ...

21 hours ago - Business Wire

Qiagen and Gencurix Enter Clinical Diagnostics Partnership

The companies said Wednesday the partnership combines Qiagen's QIAcuityDx platform, a digital polymerase chain reaction system, with Gencurix's expertise in assay development for oncology tests.

8 days ago - Market Watch

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performan...

8 days ago - Wallstreet:Online

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assa...

8 days ago - Business Wire

Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

Shares of Incyte Corporation (NASDAQ: INCY) rose sharply in today's pre-market trading . QIAGEN and Incyte disclosed a precision medicine collaboration to develop companion diagnostics for patients w...

11 days ago - Benzinga

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio...

12 days ago - Wallstreet:Online

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration t...

12 days ago - Business Wire

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

NEW YORK--(BUSINESS WIRE)--Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Sta...

21 days ago - Business Wire

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (M...

24 days ago - Wallstreet:Online

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partner...

24 days ago - Business Wire

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma

BOULDER, Colo. , Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic,...

24 days ago - PRNewsWire

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of ...

5 weeks ago - Business Wire

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

VENLO, the Netherlands & TEL AVIV, Israel--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has signed a definitive agreement to acquire Genoox,...

6 weeks ago - Business Wire

QIAGEN announces plans for transition in leadership of Supervisory Board

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to ...

7 weeks ago - Business Wire

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today confirmed strong Q1 2025 results in line with the preliminary announcement and ...

7 weeks ago - Business Wire

Qiagen declares $0.25 dividend

7 weeks ago - Seeking Alpha

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN’s s...

7 weeks ago - Wallstreet:Online